Loggie, Brian W. MD, CM, FRCSC, FACS

Loggie, Brian W. MD, CM, FRCSC, FACS

Surgical Oncology

Department of Surgery: Professor
Endowed Bonnstetter Chair
Chief of Division of Surgical Oncology
Director of Cancer Biology Program

Contact

Primary Location:
Creighton University Medical School
CHI Clinic Surgical Oncology
601 North 30th Street #2803
Omaha, NE 68131

Phone: 402.280-5292
Fax: 402.208.5979

Email Address

To request a patient appointment with Brian Loggie, click here...

Education & Training

Undergraduate Degree: CEGEP Diploma, Science, 1973; Pre-med Loyola College, Montreal, Canada, 1974

Medical Degree: M.D., C.M., McGill University, Montreal, Canada, 1979

Postgraduate Training: Internship, Department of Surgery, Montreal General Hospital, Montreal, Canada, 1979-80, Resident in Surgery, Department of Surgery, Montreal General Hospital, Montreal, Canada, 1980-86, Graduate Studies, Department of Experimental Surgery, McGill University, Montreal, Canada, 1982-86

Faculty Positions: University of Illinois at Chicago, Chicago, IL, 1986-88, Bowman Gray School of Medicine, Winston-Salem, NC, 1988-2000, University of Texas Southwestern Medical Center, Dallas, TX 2000-2002, Creighton University School of Medicine, Omaha, NE, 2002-present.

Specialty Training: Clinical and Research Fellowship in Surgical Oncology, Division of Surgical Oncology, Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, 1986-88, Specialist Certificate in General Surgery, Royal College of Physicians and Surgeons of Canada, 1986, Diplomat of the American Board of Surgery, 1990, Certificate of Training in Surgical Oncology issued from University of Illinois School of Medicine, Department of Surgery, Chicago, Illinois, 1998, Re-certification, American Board of Surgery, General Surgery 2011.

Special interests/Expertise: Surgical Oncology. Peritoneal carcinomatosis and malignant ascites, peritoneal mesothelioma, abdominopelvic and retroperitoneal sarcomas, pseudomyxoma peritonei, cutaneous malignant melanoma, sphincter preserving treatment for rectal tumors, and management of complex primary or recurrent solid tumors

Organizations/Societies:  Fellow, Royal College of Surgeons of Canada; Fellow, Society of Surgical Oncology; Fellow, American College of Surgeons; Fellow, Southeastern Surgical Congress; Member, Canadian Association of General Surgeons; Member, North Carolina Medical Society; Member, Forsyth-Stokes-Davie County Medical Society; Member, Association for Academic Surgery; Member, American Medical Association; Member, Bowman Gray Surgical Society; Member New York Academy of Sciences; Member, North Carolina Chapter, American College of Surgeons; Member, Cancer and Leukemia Group B(CALGB); Member, Southern Association for Oncology; Fellow, American College of Surgeons; Member, United States Chapter of the Societe Internationale de Chiurgie; Member, American Society of Clinical Oncology (ASCO); Member, International Society for Regional Cancer Therapy; Member, North Carolina Surgical Association; Director, Mesothelioma Applied Research Foundation (MARF)

Honors: Selected by peers for inclusion in The Best Doctors in America, 2001-present. Accepted the 2010 Magis Award from Creighton University, Omaha, Nebraska on behalf and as a leader of, a Creighton-led health team that treated victims of the Haiti earthquake. Selected by peers for inclusion Castle Connoly's America's Top Doctors 2011.


Selected Publications/Abstracts:


Shen P, Levine EA, Hall J, Case D, Russell G, Fleming RA, McQuellon RP, Geisinger KR, Loggie BW.  Factors predicting survival following intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.  Archives of Surgery, 2003, 138: 26-33.
archsurg.ama-assn.org/issues/v138n1/rfull/soa2119.html 

McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA.  Long term survivorship and quality of life following intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.  Annals of Surgical Oncology, 2003; in press.

Loggie BW, Wu Y, Saboorian MH, et al. Cox-2 and thymidylase synthase correlate with proliferative rates of mucinous tumors with diffuse peritoneal dissemination. ASCO, 2002, Abstract No: 1798.
 http://www.asco.org
 
Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999-1003.

Loggie BW. Malignant peritoneal mesothelioma. Current Treatment Options in Oncology 2001:2:395-9.

Jackson SL, Fleming RA, Loggie BW, Geisinger KR. Gelatinous ascites: A cytohistologic study of pseudomyxoma peritonei in 67 patients. Mod Pathol 2001;14:664-71.
modpath.uscapjournals.org/cgi/content/full/14/7/664

McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Onc 2001;27:65-73.

Fleming RA, Loggie BW, Russell GB, Rice MA: Systemic exposure of mitomycin C during intraperitoneal hyperthermic administration is correlated with hematologic toxicity and survival in patients with peritoneal carcinomatosis. Proc Am Assoc Cancer Res 1998;39:599.

Chen MY, Chiles C, Loggie BW, et al. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Onc 1997;66:19-23.
Loggie BW, Fleming RA, Hosseinian AA. Peritoneal carcinomatosis with urachal signet-cell adenocarcinoma: A case report. Urology 1997;50:446-8.
www.urologyonline.it/bag/carcper.txt

Loggie BW, Perini M, Fleming RA, et al. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997;63:137-43
www.sesc.org/surgeon/0297abs.htm

Loggie BW, Fleming RA, Geisinger KR. Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Acta Cytol 1996;40:1154-8.
www.acta-cytol.com

Current Research:  We have a clinical and translational research team especially focused on Pseudomyxoma Peritonei (PMP)  and Malignant Peritoneal Mesothelioma (MPM).  We are trying to identify new and better treatments.  Our team is engaged in studies looking at tumor microenvironment, inflammation, signaling pathways, and tumor models. We have been fortunate to receive generous patient sponsored support for these studies. It is more difficult to get support for the study of uncommon or rare disease that we treat through traditional funding mechanisms.  The current level of support for all research nationwide has been adversely affected by the economy.  If you are interested in knowing more about what we do or how to support us, please contact us.